| Excerpt | Reference | Relevance |
|---|
| " After initiation of peritoneal dialysis in patients with severe renal impairment (GFR < 10 ml/min) MPA area under the concentration curve (AUC) decreased substantially (15-59%)." | ( Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis.
Ahnert, V; Bauer, S; Budde, K; Fritsche, L; Kuchinke, S; Lampe, D; Mai, I; Morgera, S; Neumayer, HH, 1998) | 0.3 |
| " Because the pharmacologic activity of MPA is a function of unbound drug concentration, these findings might be relevant for the pharmacodynamic effects of MPA." | ( Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
Armstrong, VW; Lamersdorf, T; Mandelbaum, A; Mehls, O; Niedmann, PD; Oellerich, M; Schütz, E; Shipkova, M; Tönshoff, B; Weber, LT; Wiesel, M; Zimmerhackl, LB, 1998) | 0.3 |
| " Pharmacokinetic parameters of MPA estimated before and after clamping the t-tube were compared to evaluate any significant differences at a P of." | ( Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
Fung, JJ; Hamad, I; Jain, AB; Venkataramanan, R; Warty, VS; Zhang, S; Zuckerman, S, 1999) | 0.3 |
| " The pharmacokinetic parameters of MPA and MPA glucuronide (MPAG) were determined at steady state by high-performance liquid chromatography after administration of MMF at the oral dose of 494+/-142 mg/m(2) twice daily." | ( Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children.
Baudouin, V; Jacqz-Aigrain, E; Khan Shaghaghi, E; Loirat, C; Maisin, A; Popon, M; Zhang, D, 2000) | 0.31 |
| " There was no significant difference for any of the pharmacokinetic parameters between subjects on hemodialysis and those on peritoneal dialysis." | ( Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
Bewick, M; Davis, C; Eastwood, JB; Holt, DW; Johnston, A; Lee, T; MacPhee, IA; Spreafico, S, 2000) | 0.31 |
| " The increases in the AcMPAG pharmacokinetic variables were paralleled by significant increases in the corresponding MPA variables." | ( Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.
Armstrong, VW; Haley, J; Niedmann, PD; Oellerich, M; Shipkova, M; Tönshoff, B; Weber, L; Wieland, E, 2002) | 0.31 |
| " Furthermore, the pharmacokinetic characteristics of free and total MPA and its glucuronides depend directly or indirectly on graft function and the type of co-administered calcineurin-inhibitor." | ( Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Abramowicz, D; Armstrong, V; Daems, J; Kuypers, DR; Mourad, M; Oellerich, M; Shipkova, M; Squifflet, JP; Vanrenterghem, Y, 2003) | 0.32 |
| "The authors conducted a prospective 12-month multicenter pharmacokinetic study on MPA (MPA, free MPA, free fraction MPA) and its metabolites (MPAG, Acyl-MPAG)." | ( Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Abramowicz, D; Armstrong, V; Daems, J; Kuypers, DR; Mourad, M; Oellerich, M; Shipkova, M; Squifflet, JP; Vanrenterghem, Y, 2003) | 0.32 |
| "They have demonstrated that in renal transplant recipients MPA, free MPA, Acyl-MPAG and MPAG have a particular pharmacokinetic profile when combined with tacrolimus which differs from the combination with CsA." | ( Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Abramowicz, D; Armstrong, V; Daems, J; Kuypers, DR; Mourad, M; Oellerich, M; Shipkova, M; Squifflet, JP; Vanrenterghem, Y, 2003) | 0.32 |
| " More extensive pharmacokinetic measurements like area under the concentration curves might be necessary for routine therapeutic drug monitoring of MMF." | ( Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Abramowicz, D; Armstrong, V; Daems, J; Kuypers, DR; Mourad, M; Oellerich, M; Shipkova, M; Squifflet, JP; Vanrenterghem, Y, 2003) | 0.32 |
| " The coadministration of daclizumab did not result in a pharmacokinetic interaction with MPA, the active metabolite of MMF." | ( Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
Bumgardner, G; Gaston, RS; Kirkman, RL; Light, S; Nieforth, K; Patel, IH; Pescovitz, MD; Vincenti, F, 2003) | 0.32 |
| " The method developed was found to be accurate and precise in quantifying the level of MPA and MPAG over a their therapeutic range of concentrations in small volumes of plasma and thus can be effectively used in the routine drug monitoring procedures and pharmacokinetic studies." | ( Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients.
Araya, FG; Beattie, TJ; Galloway, PJ; Watson, DG, 2004) | 0.32 |
| " The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs." | ( Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
Bartosh, S; Bastien, MC; Campestrini, J; Choi, L; Ettenger, R; Niederberger, W; Schmouder, R; Zhu, W, 2005) | 0.33 |
| " This study compared the pharmacokinetic profiles of MPA and its major metabolite MPA glucuronide (MPAG) in combination with tacrolimus (TAC) or cyclosporine (CyA) during the maintenance period (>6 months) following renal transplantation." | ( Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
Hashimoto, H; Kagawa, Y; Maeda, T; Naito, T; Otsuka, A; Ozono, S; Shinno, K; Suzuki, K; Takayama, T; Ushiyama, T, 2006) | 0.33 |
| "The aim of this study was to investigate the effect of time on pharmacokinetic (PK) parameters of mycophenolic acid (MPA) in the early post-transplant period in kidney recipients." | ( Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Durlik, M; Gralak, B; Majchrnak, J; Pawinski, T; Szlaska, I; Urbanowicz, A, 2006) | 0.33 |
| "To develop a pharmacokinetic model for the enterohepatic circulation of mycophenolic acid (MPA)." | ( [Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid].
Jiao, Z; Shen, J; Yu, YQ; Zhong, LJ; Zhong, MK, 2006) | 0.33 |
| " Pharmacokinetic (PK) model was established based on physiological and biopharmaceutical consideration and PK parameters were obtained using nonlinear mixed effect model." | ( [Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid].
Jiao, Z; Shen, J; Yu, YQ; Zhong, LJ; Zhong, MK, 2006) | 0.33 |
| " The predicted time-concentration curve and AUC0-t, Cmax, Tmax estimated by the established model were in agreement with the observations." | ( [Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid].
Jiao, Z; Shen, J; Yu, YQ; Zhong, LJ; Zhong, MK, 2006) | 0.33 |
| " Pharmacokinetic profiling of MPA by determining AUC is a tool for determining drug exposure." | ( Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ensom, MH; Levy, RD; Partovi, N; Riggs, KW; Ting, LS, 2006) | 0.33 |
| "To characterize the pharmacokinetic parameters and metabolic ratios of MPA in stable adult lung transplant recipients." | ( Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ensom, MH; Levy, RD; Partovi, N; Riggs, KW; Ting, LS, 2006) | 0.33 |
| " Conventional pharmacokinetic parameters were determined via noncompartmental methods." | ( Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ensom, MH; Levy, RD; Partovi, N; Riggs, KW; Ting, LS, 2006) | 0.33 |
| "There was large interpatient variability in all pharmacokinetic parameters of MPA, MPAG, and AcMPAG." | ( Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ensom, MH; Levy, RD; Partovi, N; Riggs, KW; Ting, LS, 2006) | 0.33 |
| "Because of the large interpatient variability in the pharmacokinetic parameters of MPA, MPAG, and AcMPAG, therapeutic drug monitoring of MPA and its metabolites in lung transplant recipients may be beneficial." | ( Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ensom, MH; Levy, RD; Partovi, N; Riggs, KW; Ting, LS, 2006) | 0.33 |
| "This study aimed to investigate the pharmacokinetic characteristics of total and free mycophnolic acid (MPA) and its 7-O-glucuronide metabolite (MPAG) in Chinese renal transplant recipients." | ( Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
Jiao, Z; Lu, WY; Shi, XJ; Yu, YQ; Zhang, M; Zhong, JY, 2007) | 0.34 |
| " Whole 12-h pharmacokinetic profiles were obtained on the 10th day after operation in 12 adult Chinese de novo renal transplant recipients administrated with mycophenolate mofetil (MMF, 750 mg bid), cyclosporine and corticosteroids." | ( Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
Jiao, Z; Lu, WY; Shi, XJ; Yu, YQ; Zhang, M; Zhong, JY, 2007) | 0.34 |
| " However, the mean plasma concentration at 12 hours (Clast), drug disposition rate constant, half-life (t 1/2), and mean residence time were similar in both groups." | ( Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients.
Abt, P; Bozorgzadeh, A; Jain, A; Kashyap, R; Kwong, T; Orloff, M; Sharma, R; Tsoulfas, G; Venkataramanan, R, 2008) | 0.35 |
| " Differences in the MPA pharmacokinetic profiles confirmed large inter-patient variation of MPA exposure." | ( Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients.
Cai, W; Chen, B; Chen, H; Jin, Z; Mao, A; Wang, X; Yu, Z; Zhang, WX, 2008) | 0.35 |
| " Pharmacokinetic parameters of MPA and MPAG were compared between LN patients and Tac-treated or CyA-treated KT recipients." | ( Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
Hishida, A; Kagawa, Y; Kawakami, J; Matsushita, T; Mino, Y; Naito, T; Otsuka, A; Ozono, S; Ushiyama, T, 2008) | 0.35 |
| " The aim of the study was to develop a population pharmacokinetic model describing the relationship between MMF dose and total MPA (tMPA), unbound MPA (fMPA), total MPAG (tMPAG) and unbound MPAG (fMPAG)." | ( Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
de Winter, BC; Mathot, RA; Shaw, LM; Sombogaard, F; van Gelder, T; van Hest, RM, 2009) | 0.35 |
| "There are limited data as to the effectiveness of mycophenolate mofetil (MMF) plus high-dose corticosteroids for the treatment of acute graft-versus-host disease (aGVHD), and even less data regarding the pharmacokinetic disposition and exposure-response relationship of MMF in individuals with GVHD." | ( Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
Alousi, A; Bolaños-Meade, J; Grimley, M; Ho, V; Huang, J; Jacobson, PA; Kim, M; Levine, JE; Logan, B; Weisdorf, D; Wu, J, 2010) | 0.36 |
| " The present method was successfully applied to a pharmacokinetic study following oral administration of enterocoated sodium mycophenolate in de novo renal transplantation." | ( UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study.
Basset, T; Delavenne, X; Juthier, L; Mariat, C; Pons, B, 2011) | 0.37 |
| " Pharmacokinetic characteristics of MMF and its relation to the degree of immune suppression have not been fully clarified in clinical practice." | ( [Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice].
Naito, T, 2010) | 0.36 |
| " A 12-hour steady-state pharmacokinetic study was conducted." | ( Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.
Attwood, K; Danison, RT; DiFrancesco, R; Dole, K; Forrest, A; Gundroo, AC; Leca, N; Sudchada, P; Tornatore, KM; Venuto, RC; Wilding, GE; Zack, J, 2011) | 0.37 |
| " The method was successfully employed for pharmacokinetic studies in plasma and bile after oral administration of mycophenolate mofetil (prodrug of MPA) in rats." | ( Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile.
Gao, JW; Guo, YK; Li, XY; Liu, GL; Peng, ZH; Sun, B, 2011) | 0.37 |
| " MPA pharmacokinetic parameters were correlated with blood CsA area under the curve (AUC0-12) and graft function as measured glomerular filtration rate (GFR)." | ( Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
Cortinovis, M; Gaspari, F; Gotti, E; Perico, N; Pradini, S, 2011) | 0.37 |
| " Pharmacokinetic parameters were then analyzed by conventional noncompartmental modeling." | ( Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
Al-Khatib, M; Ensom, MH; Greanya, ED; Partovi, N; Poulin, E; Shapiro, RJ, 2012) | 0.38 |
| " pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52." | ( Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
Al-Khatib, M; Ensom, MH; Greanya, ED; Partovi, N; Poulin, E; Shapiro, RJ, 2012) | 0.38 |
| " Pharmacokinetic and pharmacodynamic parameters simultaneously obtained by the nonlinear mixed effects modeling program NONMEM explained reasonably well the concentrations of MPA and MPA glucuronide as well as IMPDH activity in both rats." | ( Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach.
Kawanishi, M; Matsubara, K; Nakagawa, S; Yano, I; Yonezawa, A; Yoshimura, K, 2015) | 0.42 |
| " Although significant pharmacokinetic changes in total MPA and MPAG levels were not observed in HL rats, there was a marked increase in free MPA and MPAG levels." | ( Effects of poloxamer 407-induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats.
Baek, YJ; Cho, YY; Kang, HE; Kim, YC; Kwon, MH; Yoon, JN, 2016) | 0.43 |
| " Limited sampling strategies (LSSs) were developed to estimate the area under the concentration curve from 0 to 12 hours (AUC0-12h) of total and free MPA." | ( Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus.
Ji, L; Jiao, Z; Liu, FY; Qiu, XY; Xu, LY; Zhang, M, 2018) | 0.48 |
| "The pharmacokinetic profile of total and free MPA and its main metabolite MPAG was examined in Chinese adult renal transplant patients receiving EC-MPS." | ( Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus.
Ji, L; Jiao, Z; Liu, FY; Qiu, XY; Xu, LY; Zhang, M, 2018) | 0.48 |
| "To define the noncompartmental pharmacokinetic (PK) parameters of three single doses of intravenous (i." | ( Noncompartmental pharmacokinetics of three intravenous mycophenolate mofetil concentrations in healthy Standardbred mares.
Burroughs, DL; Cole, LK; Guo, Y; Hill, K; Lorch, G; Phelps, MA; Schroeder, EL, 2023) | 0.91 |
| "0 mg/kg的剂量单次静脉推注给药，两次给药之间间隔8天洗脱期。在 MMF 给药前即刻和 24 h 内采集血样。根据 FDA 指南开发了液相色谱-串联质谱法，以测定血浆MMF、MPA、MPAG、AcMPAG和 MPG 浓度。单独分析血浆浓度，然后计算几何平均值和变异系数。 结果:测定了所有剂量下 MMF 和所有代谢物的非房室 PK 参数。所有马中的 MMF 均迅速转化为MPA。MMF 的每个递增剂量导致 MPA 和另外三种代谢物的 Cmax 和AUCinf_obs增加。在10倍剂量范围内，MMF及其代谢物的 Cmax 和AUCinf_obs呈非线性增加。 结论和临床相关性:马通过葡萄糖醛酸化和糖苷化清除途径，将 MMF 生物转化为MPA、MPAG、AcMPAG和MPG。确定了 MPA 及其代谢物MPAG、AcMPAG和 MPG 的马参考 PK 曲线。." | ( Noncompartmental pharmacokinetics of three intravenous mycophenolate mofetil concentrations in healthy Standardbred mares.
Burroughs, DL; Cole, LK; Guo, Y; Hill, K; Lorch, G; Phelps, MA; Schroeder, EL, 2023) | 0.91 |
| " The purpose of this study is to develop a sensitive LC-MS/MS method to simultaneously quantify MMF, MPA, and two major metabolites, mycophenolic acid-glucuronide (MPAG) and Acyl-mycophenolic acid-glucuronide (AcMPAG) and applied this method in a pharmacokinetic (PK) and tissue distribution study." | ( Development of a novel UPLC-MS/MS method for the simultaneous quantification of mycophenolic mofetil, mycophenolic acid, and its major metabolites: Application to pharmacokinetic and tissue distribution study in rats.
Abasifreke, B; Du, T; Etim, I; Gao, S; Kuddabujja, D; Liang, D; Sun, R, 2023) | 0.91 |
| Excerpt | Relevance | Reference |
|---|
| " Dosing of MPA was 2 x 1 g/day." | ( Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis.
Ahnert, V; Bauer, S; Budde, K; Fritsche, L; Kuchinke, S; Lampe, D; Mai, I; Morgera, S; Neumayer, HH, 1998) | 0.3 |
| " The areas under the concentration-time curves (AUC0-12) of total and free MPA throughout the 12-h dosing interval in children were, in general, comparable to the corresponding data in adult patients." | ( Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
Armstrong, VW; Lamersdorf, T; Mandelbaum, A; Mehls, O; Niedmann, PD; Oellerich, M; Schütz, E; Shipkova, M; Tönshoff, B; Weber, LT; Wiesel, M; Zimmerhackl, LB, 1998) | 0.3 |
| " The concentration of MPA and MPAG in plasma, bile, and urine samples obtained over one dosing interval was measured by high-pressure liquid chromatography." | ( Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
Fung, JJ; Hamad, I; Jain, AB; Venkataramanan, R; Warty, VS; Zhang, S; Zuckerman, S, 1999) | 0.3 |
| " Levels of mycophenolic acid (MPA), its glucuronide metabolite, and daclizumab were measured after dosing on days 28 and 56." | ( Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
Bumgardner, G; Gaston, RS; Kirkman, RL; Light, S; Nieforth, K; Patel, IH; Pescovitz, MD; Vincenti, F, 2003) | 0.32 |
| " The pharmacokinetic results for pediatric patients are comparable with those obtained previously in adults, although exposure based on AUC(0-infinity) was approximately 23% higher, and this finding may be a result of dosing on the basis of BSA, rather than body weight." | ( Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
Bartosh, S; Bastien, MC; Campestrini, J; Choi, L; Ettenger, R; Niederberger, W; Schmouder, R; Zhu, W, 2005) | 0.33 |
| " Twelve live donor liver transplant and 12 deceased donor liver transplant recipients were studied over a dosing interval after intravenous administration of mycophenolate mofetil." | ( Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients.
Abt, P; Bozorgzadeh, A; Jain, A; Kashyap, R; Kwong, T; Orloff, M; Sharma, R; Tsoulfas, G; Venkataramanan, R, 2008) | 0.35 |
| " Simulations were performed to assess the influence of the time of bile release after dosing (T(bile)) and the gallbladder emptying interval (tau(gall)) on the EHC process." | ( Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
Chan, E; Lou, HX; Vathsala, A; Yau, WP; Zhou, S, 2009) | 0.35 |
| " The current practice of MMF 1 gm twice daily dosing provides low plasma concentrations in many patients." | ( Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.
Alousi, A; Bolaños-Meade, J; Grimley, M; Ho, V; Huang, J; Jacobson, PA; Kim, M; Levine, JE; Logan, B; Weisdorf, D; Wu, J, 2010) | 0.36 |
| " A fixed dosing of MMF often causes bone marrow toxicity or cytomegalovirus antigenemia under the optimal dosing of calcineurin inhibitors." | ( [Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice].
Naito, T, 2010) | 0.36 |
| " The results support differential MPA dosing and the role of therapeutic drug monitoring in addition to considering the influence of renal function and concurrent immunosuppressives on MPA and MPAG pharmacokinetics." | ( Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.
Attwood, K; Danison, RT; DiFrancesco, R; Dole, K; Forrest, A; Gundroo, AC; Leca, N; Sudchada, P; Tornatore, KM; Venuto, RC; Wilding, GE; Zack, J, 2011) | 0.37 |
| "Thirty-one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000-2000mg/day) for at least 1month and who had not experienced any adverse drug reactions for more than 3months were enrolled." | ( Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
Kawakami, J; Mino, Y; Naito, T; Ogawa, N; Shimoyama, K, 2012) | 0.38 |
| "MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94-2·96 and 18·6-53·7μg/mL, respectively." | ( Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
Kawakami, J; Mino, Y; Naito, T; Ogawa, N; Shimoyama, K, 2012) | 0.38 |
| "Upon administration of steady-state morning tacrolimus and mycophenolate mofetil doses, 28 patients for whom at least three months had passed after renal transplantation underwent serial blood sample collection over a 12-hour dosing period." | ( Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
Al-Khatib, M; Ensom, MH; Greanya, ED; Partovi, N; Poulin, E; Shapiro, RJ, 2012) | 0.38 |
| " The aim of this study was to establish the optimal dosage and administration of immunosuppressants and antifungal agents." | ( [Optimization of Immunosuppression and the Prevention of Fungal Infection in Autoimmune Diseases].
Mino, Y, 2015) | 0.42 |